Prevenar 13® Adult Private Vaccination

Prevenar 13® is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age and the elderly.1

  • Each year, up to 1 in every 100 UK adults develop pneumonia. Pneumonia can be caused by viruses, bacteria and fungi. Streptococcus pneumoniae is the most common bacterial cause.2,3

  • Offer adults the proven, lasting protection of Prevenar 13® all year round.4*

  • People can choose to pay privately for a vaccination, to help protect themselves with Prevenar 13®.

* vs placebo.4 Data from a randomised, placebo-controlled, double-blind trial demonstrated the efficacy of Prevenar 13® vs placebo in the prevention of a first episode of confirmed vaccine-type community-acquired pneumococcal pneumonia in adults aged > 65 years of age.4 Post-hoc analysis showed that the efficacy of Prevenar 13® vs placebo persisted throughout the 4-year trial.4

Risk Groups

Pneumococcal pneumonia can strike people of any age.3 However, many factors put adults at increased risk of pneumococcal infections, including pneumococcal pneumonia, making them potential candidates for vaccination. 3,5-11

risk_groups
  • Aged>45 years: The risk of contracting pneumococcal pneumonia increases from the age of 45 onwards.5-7 
  • Smoking: Smokers are 4.4 times more likely to develop pneumonia than someone who has never smoked.11 
  • Exposure to lots of people in close contact: Examples of this include the Hajj and Umrah pilgrimages. A 2.7 fold increase in nasal carriage rate of Streptococcus pneumoniae was reported in pilgrims returning from Hajj in 2012.10
  • Travelling: Many of the world’s most popular tourist destinations13, including South Asia and parts of Africa are also home to higher levels of pneumococcal infections.12 Some countries, like China and Thailand, do not routinely immunise against pneumococcal disease at all.14 Others, like India, have only started vaccinating recently.14
  • Chronic conditions including asthma, respiratory disease, heart disease, diabetes, liver disease and kidney disease.11
  • Those who have already had pneumonia or have flu: People who have had pneumonia in the past are twice as likely to get pneumonia again compared with people who have never had pneumonia. Those who have a flu infection are 100 times more likely to develop pneumonia.15,16

 

There are a lot of occasions where you can help protect your patients with Prevenar 13® vaccination.12

Risk data above is for people aged 50-64. People aged 18-49 and ≥ 65 had lower ratios. 

For more information or supply enquiries 

Contact our Pfizer Vaccines team on: 0800 089 4033 or email [email protected]

References

  1. Prevenar 13® Summary of Product characteristics. Available at https://www.medicines.org.uk/emc/product/453. June 2020.
  2. Lim W, Baudouin S, George R et al. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3): iii1 -iii55.
  3. NHS UK. Pneumonia. Available at https://www.nhs.uk/conditions/pneumonia/. Last accessed June 2020.
  4. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25.
  5. Miller E,  Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. LancetInfectDis 2011;11:760-768.
  6. Hospital Episodes statistics data accessed March 2018. Ages >16, ICD-10 codes J12-J18, England only data.
  7. Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax Epub 2019;0:1-12.
  8. Public Health England. The Green Book, Chapter 25: Pneumococcal. Available at: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25. Last accessed June 2020.
  9. Public Health England. Guidelines for the public health management of clusters of severe pneumococcal disease in closed settings. Available at: https://www.gov.uk/government/publications/managing-clusters-of-pneumococcal-disease-in-closed-settings. Last accessed June 2020.
  10. Benkouiten S, Gautret P, Belhouchat K, et al. Acquisition of Streptococcus pneumoniae carriage in pilgrims during the 2012 Hajj. Clin Infect Dis. 2014;58(4):e106-9.
  11. Shea KM, Edelsburg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open forum Infect Dis. 2014;1-9.
  12. Ferreira D, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol. 2011;19(9):464-70. 
  13. World Tourism Organisation. International tourism highlights 2019. Available at: https://www.e-unwto.org/doi/pdf/10.18111/9789284421152. Last accessed June 2020.
  14. International Vaccine Access Centre (IVAC), View-hub. Available at: https://www.view-hub.org. Last accessed June 2020.
  15. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84.
  16. Shrestha S, Foxman B, Berus J, et al. The role of influenza in the epidemiology of pneumonia. Sci Rep. 2015 Oct 21;5:15314.

Prescribing Information
Prevenar 13® prescribing information.

 

PP-PNA-GBR-0421.  July 2020